Visilizumab |
| カタログ番号GC72365 |
Visilizumab（抗ヒトCD 3 E組換え抗体）は、ヒト化低Fc受容体結合の抗CD 3モノクローナルIgG 2抗体である。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 219716-33-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Visilizumab induces dose- and time-dependent apoptosis of lamina propria T cells. Visilizumab-induces apoptosis of lamina propria T cells is dependent on caspase 3 and 8, but not caspase 9 activation and does not involve the Fas/FasL pathway[1].
References:
[1]. Qi T Yu, et al. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *